Previous close | 0.7407 |
Open | 0.7500 |
Bid | 0.7350 x 2900 |
Ask | 0.7600 x 1800 |
Day's range | 0.7015 - 0.7570 |
52-week range | 0.6000 - 4.5400 |
Volume | |
Avg. volume | 2,385,885 |
Market cap | 120.918M |
Beta (5Y monthly) | 2.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 18 Dec 2012 |
1y target est | N/A |
HENDERSON, Nev., May 26, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7.
HENDERSON, Nev., May 17, 2022--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations beginning on May 24, 2022 at
HENDERSON, Nev., May 12, 2022--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update.